Text Size
193 studies found for:    nasopharyngeal cancer | "Nasopharyngeal Neoplasms"

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
21 Recruiting Screening for Nasopharyngeal Carcinoma in High Risk Populations
Conditions: Nasopharyngeal Cancer;   Screening
Intervention:
22 Completed Bortezomib and Gemcitabine in Treating Patients With Recurrent or Metastatic Nasopharyngeal Cancer
Conditions: Recurrent Nasopharyngeal Cancer;   Stage IV Nasopharyngeal Cancer
Interventions: Drug: bortezomib;   Drug: gemcitabine hydrochloride;   Other: laboratory biomarker analysis
23 Unknown † Weekly Docetaxel Plus Cisplatin as the First-line Therapy for Nasopharyngeal Cancer
Condition: Nasopharyngeal Cancer
Intervention: Drug: Docetaxel, Cisplatin
24 Recruiting Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma
Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Recurrent Lymphoepithelioma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Stage IV Lymphoepithelioma of the Nasopharynx;   Stage IV Squamous Cell Carcinoma of the Nasopharynx
Interventions: Drug: azacitidine;   Drug: vorinostat;   Other: diagnostic laboratory biomarker analysis;   Other: pharmacological study;   Procedure: axillary lymph node biopsy
25 Completed Swallowing Pattern of Patients With Nasopharyngeal Cancer Before and After Radiation Therapy: Longitudinal Study and Correction With Saliva Amount
Condition: Nasopharyngeal Carcinoma
Intervention:
26 Recruiting Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Carcinoma
Interventions: Drug: Icotinib;   Radiation: intensity-modulated radiotherapy;   Drug: Paclitaxel and Cisplatin;   Other: Quality of life;   Genetic: Epidermal growth factor receptor status
27 Recruiting A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma
Conditions: Nasopharyngeal Cancer;   Epstein Barr Virus Infections
Intervention: Drug: MVA-EBNA1/LMP2 vaccine
28 Completed T-Lymphocytes in Treating Patients With Epstein-Barr Virus-Positive Nasopharyngeal Cancer, NPC
Condition: Head and Neck Cancer
Intervention: Biological: autologous EBV specific CTLs
29 Recruiting Induction Chemotherapy and Chemoradiotherapy in Nasopharyngeal Cancers
Condition: Nasopharyngeal Cancers
Intervention: Procedure: Induction chemotherapy + concurrent radiochemotherapy vs. concurrent radiochemotherapy
30 Unknown † Cisplatin and Radiation Therapy With or Without Gemcitabine Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Locally Advanced Nasopharyngeal Cancer
Condition: Head and Neck Cancer
Interventions: Drug: carboplatin;   Drug: cisplatin;   Drug: gemcitabine hydrochloride;   Drug: paclitaxel;   Radiation: intensity-modulated radiation therapy
31 Completed A Study of Xeloda (Capecitabine) in Combination With XELOX (Oxaliplatin) in Patients With Metastatic Nasopharyngeal Cancer.
Condition: Nasopharyngeal Cancer
Interventions: Drug: capecitabine [Xeloda];   Drug: Oxaliplatin
32 Completed Radiation Therapy With or Without Chemotherapy in Reducing Mouth Dryness in Patients With Nasopharyngeal Cancer
Conditions: Head and Neck Cancer;   Oral Complications of Radiation Therapy;   Radiation Toxicity
Interventions: Drug: cisplatin;   Drug: fluorouracil;   Procedure: adjuvant therapy;   Procedure: assessment of therapy complications;   Procedure: quality-of-life assessment;   Radiation: radiation therapy
33 Unknown † Positron Emission Tomography Scanning and Epstein-Barr Virus DNA Levels in the Staging and Follow-Up of Nasopharyngeal Carcinoma.
Condition: Nasopharyngeal Carcinoma
Intervention:
34 Recruiting GC Regimen Chemotherapy Plus CIK Cells for Metastatic Nasopharyngeal Carcinoma
Condition: Stage IV Nasopharyngeal Carcinoma
Interventions: Drug: GC chemotherapy plus CIK cells (Gemcitabine, Cisplatin, Autologous CIK cells);   Drug: GC chemotherapy (Gemcitabine, Cisplatin)
35 Unknown † Induction and Concurrent Chemoradiotherapy With Cetuximab for Patients With Locally Advanced Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Carcinoma
Intervention: Drug: Cetuximab
36 Completed Late-Course Accelerated Hyperfractionated IMRT for Locoregionally Advanced Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Carcinoma
Interventions: Radiation: Late-course accelerated hyperfractionated IMRT;   Drug: Concomitant cisplatin chemotherapy;   Radiation: Conventionally fractionated IMRT
37 Unknown † Fluorouracil, Cisplatin, and Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Nasopharyngeal Cancer
Condition: Head and Neck Cancer
Interventions: Drug: cisplatin;   Drug: fluorouracil;   Radiation: radiation therapy
38 Active, not recruiting Proton Radiotherapy With Chemotherapy for Nasopharyngeal Carcinoma
Condition: Nasopharyngeal Carcinoma
Interventions: Radiation: Proton/Photon Radiotherapy;   Drug: Cisplatin;   Drug: Fluorouracil
39 Recruiting Phase II Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC)
Conditions: Stage II Lymphoepithelioma of the Nasopharynx;   Stage II Squamous Cell Carcinoma of the Nasopharynx;   Stage III Lymphoepithelioma of the Nasopharynx;   Stage III Squamous Cell Carcinoma of the Nasopharynx;   Stage IV Lymphoepithelioma of the Nasopharynx;   Stage IV Squamous Cell Carcinoma of the Nasopharynx
Interventions: Drug: docetaxel;   Drug: cisplatin;   Drug: carboplatin;   Drug: fluorouracil;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
40 Active, not recruiting Induction Chemotherapy Followed by Concurrent Radiation With Cetuximab or Cisplatin in Locally Advanced Nasopharyngeal Cancer
Condition: Nasopharyngeal Carcinoma
Interventions: Drug: Cetuximab;   Drug: Cisplatin;   Drug: Docetaxel;   Radiation: Intensity-modulated radiotherapy
To Top

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
† Indicates status has not been verified in more than two years